Swedish Dilafor extends reach to Asia in deal with Lee’s for obstetrics drug candidate
By Cornelia Zou
Wednesday, February 26, 2014
HONG KONG – Stockholm-based Dilafor AB inked a licensing agreement for its tafoxiparin, a drug designed to prevent protracted labor, with Hong Kong’s Lee’s Pharmaceutical Holdings Ltd. (HK:0950).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.